​

Cytek Biosciences (CTKB) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CTKB Stock Forecast

Cytek Biosciences (CTKB) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $5.25, with a high of $5.25 and a low of $5.25. This represents a -6.42% decline from the last price of $5.61.

$4 $5 $6 $7 $8 $9 $10 High: $5.25 Avg: $5.25 Low: $5.25 Last Closed Price: $5.61

CTKB Stock Rating

Cytek Biosciences stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

CTKB Price Target Upside V Benchmarks

TypeNameUpside
StockCytek Biosciences-6.42%
SectorHealthcare Stocks 25.00%
IndustryMedical Device Stocks6.94%

Price Target Trends

1M3M12M
# Anlaysts112
Avg Price Target$5.25$5.25$6.88
Last Closing Price$5.61$5.61$5.61
Upside/Downside-6.42%-6.42%22.64%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Feb, 25122-16
Jan, 25222--6
Dec, 24222--6
Nov, 24232--7
Oct, 24232--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Feb 02, 2025Matthew SykesGoldman Sachs$5.25$5.151.94%-6.42%
May 13, 2024Dave WestenbergPiper Sandler$8.50$6.1538.21%51.52%
Aug 17, 2022David WestenbergPiper Sandler$16.00$14.0813.64%185.20%
May 15, 2022David WestenbergPiper Sandler$12.00$9.3827.93%113.90%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
May 13, 2024Piper SandlerOverweightOverweighthold
Dec 14, 2023StephensPositiveinitialise
Oct 24, 2023Morgan StanleyEqual-WeightEqual-Weighthold
Aug 17, 2022Piper SandlerOverweightOverweighthold
Jul 19, 2022Piper SandlerOverweightOverweighthold
May 15, 2022Piper SandlerOverweightOverweighthold
May 12, 2022Goldman SachsBuyBuyhold

Financial Forecast

EPS Forecast

Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.05$0.02$-0.09-----
Avg Forecast$0.11$0.09$-0.03$0.10$0.15$0.20$0.18$0.24
High Forecast$0.10$0.09$-0.05$0.08$0.13$0.06$0.17$0.23
Low Forecast$0.11$0.09$-0.02$0.13$0.16$0.41$0.19$0.25
Surprise %-54.55%-77.78%200.00%-----

Revenue Forecast

$100M $150M $200M $250M $300M $350M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$127.95M$164.04M$193.01M-----
Avg Forecast$125.42M$166.42M$190.85M$202.99M$220.85M$243.98M$288.70M$317.00M
High Forecast$122.77M$161.00M$182.74M$202.52M$216.83M$240.04M$277.52M$304.72M
Low Forecast$128.52M$170.68M$198.96M$203.91M$223.08M$247.92M$297.30M$326.45M
Surprise %2.02%-1.43%1.13%-----

Net Income Forecast

$-15M $0 $15M $30M $45M $60M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.42M$2.58M$-12.15M-----
Avg Forecast$14.54M$12.18M$-4.51M$14.04M$20.21M$32.08M$24.35M$32.47M
High Forecast$14.14M$11.66M$-6.31M$10.80M$18.25M$8.55M$23.13M$30.83M
Low Forecast$15.01M$12.58M$-2.71M$17.28M$22.16M$55.60M$25.29M$33.73M
Surprise %-69.63%-78.84%169.39%-----

CTKB Forecast FAQ

Is Cytek Biosciences stock a buy?

Cytek Biosciences stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cytek Biosciences is a favorable investment for most analysts.

What is Cytek Biosciences's price target?

Cytek Biosciences's price target, set by 4 Wall Street analysts, averages $5.25 over the next 12 months. The price target range spans from $5.25 at the low end to $5.25 at the high end, suggesting a potential -6.42% change from the previous closing price of $5.61.

How does Cytek Biosciences stock forecast compare to its benchmarks?

Cytek Biosciences's stock forecast shows a -6.42% downside, underperforming the average forecast for the healthcare stocks sector (25.00%) and underperforming the medical device stocks industry (6.94%).

What is the breakdown of analyst ratings for Cytek Biosciences over the past three months?

  • February 2025: 16.67% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 16.67% Strong Sell.
  • January 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Cytek Biosciences’s EPS forecast?

Cytek Biosciences's average annual EPS forecast for its fiscal year ending in December is $0.1 for 2024, a -211.11% decrease from the reported $-0.09 in 2023. The prediction for 2025 is $0.15, $0.2 for 2026, $0.18 for 2027, and $0.24 for 2028.

What is Cytek Biosciences’s revenue forecast?

Cytek Biosciences's average annual revenue forecast for its fiscal year ending in December is $202.99M for 2024, a 5.17% increase from the reported $193.02M in 2023. The forecast for 2025 is $220.85M, $243.98M for 2026, $288.7M for 2027, and $317M for 2028.

What is Cytek Biosciences’s net income forecast?

For its fiscal year ending in December, Cytek Biosciences's average annual net income forecast is $14.04M for 2024, reflecting a -215.57% decrease from the reported $-12.148M in 2023. The projection for 2025 is $20.21M, $32.08M for 2026, $24.35M for 2027, and $32.47M for 2028.